Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease.

Gori, A; Rossi, M C; Marchetti, G; Trabattoni, D; Molteni, C; Cogliati, M; Bandera, A; Clerici, M; Franzetti, F

Gori, A; Rossi, M C; Marchetti, G; Trabattoni, D; Molteni, C; Cogliati, M; Bandera, A; Clerici, M; Franzetti, F.

Affiliation

Gori A; Institute of Infectious Diseases and Tropical Medicine, University of Milan, Italy.

AIDS ; 14(12): 1859-61, 2000 Aug 18.

Article in En | MEDLINE | ID: mdl-10985328

Subject(s)

Antitubercular Agents/therapeutic use; Cytokines/biosynthesis; HIV Seronegativity/immunology; HIV Seropositivity/immunology; Thalidomide/therapeutic use; Tuberculosis/drug therapy; Adult; CD4 Lymphocyte Count; Cytokines/drug effects; Female; HIV Seropositivity/complications; Humans; Male; Middle Aged; Time Factors; Viral Load

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thalidomide / Tuberculosis / Cytokines / HIV Seropositivity / HIV Seronegativity / Antitubercular Agents Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: AIDS Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2000 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links